The biopharma industry’s clinical pipeline is reaching its largest and most diverse in history. The number of distinct drugs in development has nearly doubled, growing from 3,200 in 2012 to 6,100 in 2022.1 Driven by the rising prevalence of chronic diseases like diabetes and rheumatoid arthritis and increased interest in GLP-1 antagonists, the monoclonal antibodies (mAbs) market is expanding at a compound annual growth rate (CAGR) of nearly 12% to exceed $236 billion by 2025.2 In the U.S. market, the FDA’s recent adjustments to interchangeability requirements for biosimilars3 have streamlined the process of bringing a biosimilar to market.